As shown in Figure 7B, anti-TNF treatment administered early (beginning at 6 weeks post-infection) further significantly decreased NFATp−/− survival by 20 to 28 days (median survival for NFATp−/−+PBS mice was 145 vs. 117 for NFATp−/−+Enbrel mice; p = 0.003). This evidence concerns the gene NFATC2 and infection.